Canadian drugmaker Valeant has lost billions off its market value after questions over its drug pricing and accounting. Rob Armstrong, head of Lex, reviews the warning signs for the pharmaceuticals group.
► Subscribe to the Financial Times on YouTube:
For more video content from the Financial Times, visit http://www.FT.com/video
Twitter https://twitter.com/ftvideo
Facebook https://www.facebook.com/financialtimes
